Related Experiment Video

Updated: May 11, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Anticancer activities of PPARγ in breast cancer are context-dependent

Jin-Tang Dong1

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.

The American Journal of Pathology
|April 27, 2013
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARγ) activation inhibits non-invasive tumor growth and promotes estrogen receptor-positive (ER-positive) tumors. However, it does not impact invasive tumor development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor involved in various cellular processes.
  • Tumorigenesis involves complex pathways, including those regulated by nuclear receptors.
  • Estrogen receptor (ER) status is critical in breast cancer classification and treatment.

Purpose of the Study:

  • To comment on the findings regarding PPARγ activation and its effects on tumor development.
  • To highlight the specific impact of PPARγ on non-invasive versus invasive tumor growth.
  • To emphasize the induction of ER-positivity by PPARγ activation.

Main Methods:

  • Commentary on existing research findings.
  • Analysis of the role of PPARγ activation in preclinical models.
  • Review of data on tumor development and ER status.

Main Results:

  • PPARγ activation significantly suppresses non-invasive tumor development.
  • PPARγ activation leads to the induction of ER-positivity in tumors.
  • PPARγ activation does not appear to affect invasive tumor development.

Conclusions:

  • PPARγ activation presents a potential therapeutic strategy for specific aspects of tumor development.
  • The induction of ER-positivity warrants further investigation in the context of cancer therapy.
  • Distinguishing between non-invasive and invasive tumor behavior is crucial when considering PPARγ modulation.

More Related Videos

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp111:02

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...